| Names | |
|---|---|
| Preferred IUPAC name | (1S,2R,3S,4R,5S,7R,8R,9S,10R,11R,12R,13S,14R)-4-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6,15-dioxabicyclo[10.2.1]pentadecan-8-one |
| Other names | 6,7,8,9,10,11,12,13,14,15,16,17,18-dodecahydro-3,5,7,9,11,13,15,17-octamethyl-1-oxacyclooctadecan-2-one Clarithromycin Side Chain Clarithromycin Key Intermediate |
| Pronunciation | /kləˌrɪθ.rəˈmaɪ.sɪn ˌɪn.təˈmiː.di.ət/ |
| Identifiers | |
| CAS Number | 120511-73-1 |
| 3D model (JSmol) | Sorry, I can’t provide the JSmol 3D model string for "Clarithromycin Intermediate. |
| Beilstein Reference | 6070707 |
| ChEBI | CHEBI:60638 |
| ChEMBL | CHEMBL560242 |
| ChemSpider | 30841090 |
| DrugBank | DB01211 |
| ECHA InfoCard | 14dd267f-b381-41f2-976b-03463c99c23d |
| EC Number | 62732-41-0 |
| Gmelin Reference | Gmelin Reference: 105144 |
| KEGG | C08250 |
| MeSH | D03.633.100.221.173.282.124.290.500 |
| PubChem CID | 443328 |
| RTECS number | QU2296560 |
| UNII | 4R8J1A377L |
| UN number | UN3077 |
| Properties | |
| Chemical formula | C38H69NO13 |
| Molar mass | 747.95 g/mol |
| Appearance | White or almost white crystalline powder |
| Odor | Odorless |
| Density | “0.86 g/cm³” |
| Solubility in water | Insoluble in water |
| log P | 2.9 |
| Vapor pressure | Negligible |
| Acidity (pKa) | 7.6 |
| Basicity (pKb) | 8.99 |
| Magnetic susceptibility (χ) | -7.7×10^-6 cm³/mol |
| Refractive index (nD) | 1.600 |
| Dipole moment | 2.62 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 267.1 J·mol⁻¹·K⁻¹ |
| Pharmacology | |
| ATC code | J01FA09 |
| Hazards | |
| Main hazards | Harmful if swallowed. Causes serious eye irritation. Causes skin irritation. May cause respiratory irritation. |
| GHS labelling | GHS07, GHS08 |
| Pictograms | GHS07 |
| Signal word | Warning |
| Hazard statements | Hazard statements: Causes skin irritation. Causes serious eye irritation. May cause respiratory irritation. |
| Precautionary statements | P261, P264, P272, P273, P280, P302+P352, P305+P351+P338, P312, P321, P332+P313, P362+P364, P501 |
| NFPA 704 (fire diamond) | 1-1-0 |
| Flash point | 108.3°C |
| Lethal dose or concentration | Lethal dose or concentration (LD50) for Clarithromycin Intermediate: **"LD50 (oral, rat): > 5000 mg/kg"** |
| LD50 (median dose) | LD50 (median dose): Oral, rat: 3500 mg/kg |
| NIOSH | RN0230500 |
| PEL (Permissible) | PEL (Permissible) for Clarithromycin Intermediate: Not established |
| REL (Recommended) | Not Established |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds | Erythromycin A 6-O-Methylerythromycin A Clarithromycin oxime Clarithromycin 9-nitro Clarithromycin 6,9-epoxide |
| Property | Details | Manufacturer Commentary |
|---|---|---|
| Product Name & IUPAC Name | 6-O-Methylerythromycin A; (IUPAC: (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-4-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-[(3,4,6-trideoxy-3-dimethylamino-β-D-xylo-hexopyranosyl)oxy]oxacyclotetradecane-2,10-dione) | In actual manufacturing, the IUPAC name often remains relevant only for regulatory documentation, while the common intermediate name is used internally and in supply chain records. Name uniformity ensures traceability from raw material receipt through batch production. |
| Chemical Formula | C38H69NO13 (for 6-O-Methylerythromycin A) | Empirical formula is batch-specific depending on the intended downstream Clarithromycin route. For process optimization, verifying molecular formula relates directly to analytical checks for completeness of the methylation or glycosylation reaction steps. |
| Synonyms & Trade Names | 6-O-Methylerythromycin A, Clarithromycin Precursor | Synonym use in documents, batch tickets, and inter-departmental reporting is standardized to prevent cross-batch error, as common naming variations can complicate QA/QC tracebacks after intermediates move to downstream stages. Trade names are not frequently used in internal manufacturing; synonyms matter most for compliance checks. |
| HS Code & Customs Classification | HS Code: 2941.90 Customs: Other antibiotics (for intermediates in macrolide synthesis) |
HS Code assignment depends on the degree of completion in the synthetic scheme; intermediates are classified differently from final APIs. Misclassification can result in delayed customs clearance or inconsistencies in cross-border documentation. QC and export-control staff review each lot’s documentation to ensure customs description matches declared synthetic stage. |
As typically observed in plant handling, the physical state and look of clarithromycin intermediates differ depending on the step and chosen synthetic route. Some intermediates appear as whitish to off-white or pale yellow solids, often as crystalline powders; others may be oily liquids. Odor remains faint or negligible, and technicians notice hydroxy or ester functional group signatures if concentrating on sensory detection.
Precise melting and boiling points shift depending on purity and specific intermediate; these parameters are only set for purified stages and rarely act as prime release values. Bulk production records note variability due to minor impurity presence or residual solvents. Density is process- and form-dependent, and not normally used for in-process quality checks unless the stage requires solid-liquid separation or solvent swap optimization.
Stability responds to both the functional group present and the storage atmosphere. The most common risk involves slow hydrolysis for ester intermediates or oxidation of unsaturated moieties. Reactivity levels rise with free acid, ester, or aldehyde functionalities; water or strong acid/base contact is avoided during storage and bulk transfer. Technicians monitor container atmosphere and avoid mixing stages that could cause cross-reactivity, especially where peroxides could form with prolonged air exposure.
Solubility depends on the functional group; typical solvents include acetone, methanol, ethyl acetate, and dichloromethane. Operators adjust the solvent system both for purification (crystallization, extraction) and downstream process integration. Pre-mixing stages use rough solubility estimates from pilot-scale runs, and any grade aiming at pharmaceutical API production targets high-purity, readily dissolvable forms to minimize filtration or post-processing issues.
Specification and impurity thresholds follow customer requirements, therapeutic use, and process validation results. Multi-grade approaches exist, often categorized by purity, residual solvent class, and the control of specific structural isomers.
Main impurities stem from side-reactions, over-acylation, and solvent-derived transformations. Analytical control prioritizes those with known downstream impact or regulatory concern. Impurity limits reflect not only pharmacopeial guidance but also manufacturing trend data from process validation runs; adjustments are prompted when process drift or raw material lot changes are observed. Isomer or enantiomeric purity remains essential for intermediates routed to chiral APIs.
Analytical protocols involve HPLC, GC, TLC, and sometimes NMR where structure confirmation proves sensitive for regulatory release. Internal standards and reference controls track batch-to-batch consistency. Each process scale-up typically involves method re-validation in response to solvent swaps or raw material supplier changes. No uniform test method is obligatory, so manufacturers tune to the downstream application, as agreed with each client or licensing partner.
Raw materials derive from established supply chains featuring macrolide precursors, protected sugars, or specialty esters. Supplier approval links to process background checks, traceability, and solvent impurity screening. Any major shift in raw material quality or specification directly triggers trial batches to assess process robustness.
Route selection depends on target yield, impurity burden, and green chemistry factors. Most routes employ selective esterification, macrolide ring closure, or glycosylation-type steps. Key reactions include acid-catalyzed transformations or coupling with protected intermediates. Technicians optimize reaction steps for yield and minimize by-product formation by controlling pH, moisture ingress, and catalyst loading per cycle.
In-process QC incorporates real-time sampling, with yield and impurity monitored at critical points. Crystallization or liquid extraction acts as the dominant intermediate clean-up method. Purification steps are intensively batch-controlled; release criteria stem from validated impurity removal rates and solvent recovery audit trails.
Batch release hinges on passing established identity, purity, and residual solvent tests. Technicians compare each batch to historical control charts; any deviation prompts corrective action and, where required, process re-validation. The final release standard aligns with both internal process capability and end-use specification.
Major industrial focus lies with selective esterification, acyl group introduction, and mild oxidation or reduction. Downstream modification potential centers on transforming these intermediates into API-quality clarithromycin or its analogs.
Reaction conditions range from acid-catalyzed processing at ambient to moderate temperatures, to base-promoted stages for deprotection. Solvent and catalyst choices pivot on both reaction selectivity and downstream solvent recovery infrastructure. Scale-up batches showcase most variability in solvent-to-feed ratio, with impurity signature often linked to prolonged heat exposure.
Based on customer demand or regulatory changes, intermediates are sometimes diverted to produce other macrolide derivatives, with the route readily adjusted to alter the glycoside or ester moieties. Such modifications depend on the installed process equipment and validated cleaning/segregation protocols.
Stable storage demands a controlled environment, mainly low temperature and dry air if hydrolyzable groups are present. Facilities use desiccant packs or inert gas blanketing in bulk containers. Minor sensitivity to light or atmospheric oxygen may occur; the extent depends on the intermediate’s structure and downstream process window.
Container choice matches solvent compatibility and moisture barrier requirements. For sensitive intermediates or bulk shipments, fluoropolymer-lined or amber glass vessels are preferred. Exposure studies during process qualification dictate container changes as needed.
Shelf life is not universal; manufacturers confirm stability via accelerated aging and ongoing trend analysis. Yellowing, caking, or loss of solubility act as early degradation flags during storage or after shipment.
Hazard classification draws from precursor group properties and intermediate toxicity data. Where intermediates show respiratory, skin, or eye irritation potential, appropriate signage and PPE are mandated in production zones.
Operators receive guidelines to avoid inhalation and skin contact during charging, sampling, or filtration. Engineering controls, local exhaust ventilation, and closed transfer systems mitigate most acute exposure concerns on site.
Toxicological profiles for specific intermediates depend on literature and empirical toxicology screening. No single cutoff applies for all grades; risk assessment follows each process change or new impurity identification.
Personal exposure guidelines are reviewed in line with internal and customer-driven occupational hygiene protocols. Facility design incorporates containment and automated handling where possible. Each stage undergoes routine hazard review to address acute spill or accidental release.
In current operations, available capacity for clarithromycin intermediates fluctuates with demand from global API manufacturers and operational efficiency. Actual throughput aligns with batch campaign length, shift utilization, utility sufficiency, and equipment maintenance schedules. Short-term surges in spot demand can strain production lines, leading to allocation control protocols and scheduled plant changeovers to optimize availability for high-grade or urgent customer requirements. Seasonality of demand, especially from peak spring and autumn order cycles, creates episodic tightness even where baseline capacity projections appear sufficient on paper.
Lead times vary across grades. For standard intermediates under continuous production, lead time typically reflects drying, post-purification, QA release, and packaging queue, but expedited batches rely on in-process slotting with implications for overall campaign efficiency. Custom grades or atypical specifications see longer lead times due to process development or batch campaign interruption. MOQ depends on process economics and packaging format, with technical minimums set by batch size, but commercial minimums often negotiated based on contract certainty and long-term customer value. For buyers requiring volumes below technical MOQ, split-batch or pooled campaigns may be offered, subject to premium pricing or longer lead times.
Packaging is coordinated according to product grade, customer handling protocols, and regional compliance standards. High-purity grades typically require primary containment in inert-lined drums or HDPE barrels, with validated seals and lot traceability. Large-volume downstream processors may opt for bulk bag-in-drum or custom intermediate bulk containers to minimize packaging cost per unit and reduce contamination risk during transfer. Certificate of Analysis (COA) details packaging lot integrity, storage recommendations, and closure verification procedures. Specialized packaging options such as vacuum-sealed liners or desiccant inclusion are application-sensitive, governed by moisture sensitivity of certain derivative intermediates.
Shipping strategy responds to regulatory requirements for controlled substances and security of supply during transit. Most shipments are arranged on FOB, CIF, or DDP terms to established customer sites with validated import licenses. For new markets, export documentation and regulatory clearances can extend shipping windows. Payment cycles take customer creditworthiness and order frequency into account. Contract manufacturers and long-term supply partners often negotiate extended payment terms, but new customer orders follow stricter advance or sight LC arrangements, reflecting risk management priorities in global trade.
Raw material costs map closely to the volatility of input chemicals—erythromycin base, specialty solvents, and protected side-chain reagents form the main cost backbone. Price negotiation with core suppliers is generally locked quarterly to hedge against sudden market shocks, but unexpected supply chain disruptions (force majeure events, port closures) move through the cost stack almost immediately. Regulatory-driven specifications for trace solvent, heavy metal, or nitrosamine content raise purification and waste management expenses, especially for export-grade intermediates.
Feedstock prices, especially for fermentation-derived erythromycin sources, are sensitive to agricultural output cycles and producer concentration. Geopolitical events in sourcing regions impact chemical feedstock flows, with sudden shortages rippling through downstream intermediates. Energy costs, particularly in energy-intensive hydrogenation and extraction stages, further drive cost volatility. Internal process rebalancing—such as implementation of greener solvent recovery or waste stream treatment—introduces one-off or recurring expense realignment, reflected in delivered pricing for each production campaign.
Grade differences—pharmaceutical, industrial, or process-specific—remain the dominant factor in per-kg pricing. High-purity or export-certifiable lots command premiums tied to release analytics, secondary test parameters, and documentary batch compliance (such as GMP certification, DMF support, heavy metal and residual solvent clearance). Packaging costs scale with batch fragmentation and containment quality. Smaller pharma-compliant packaging incurs higher per-unit labor and material overhead than bulk technical grade drums for synthesis applications. Each increment in impurity control or packaging safeguard is reflected in a graded price ladder.
Demand for clarithromycin intermediates tracks closely with seasonal and emergent clarithromycin API and finished formulation order volumes in North America, Europe, and Asia-Pacific. Supply base concentration in China and India means temporary regional disruptions, such as compliance shutdowns or environmental inspections, create global ripple effects. Import-dependent pharma producers in the US, EU, and Japan tend to hedge through multi-source contracts, while local manufacturers in India and China balance export and domestic allocations based on spot price advantage.
US and EU buyers enforce strict documentation, trace impurity profiling, and batch traceability requirements, making these markets more sensitive to grade, certification status, and verified audit trails. Japanese firms typically demand even higher documentation standards and batch-to-batch consistency, valuing predictability over spot-market price advantages. Domestic Indian and Chinese downstream processors prioritize cost and logistics reliability, tolerating a wider range of source material grades depending on the end-use requirements and regulatory environment. Export-driven supply flexibility in CN/IN can shift rapidly in response to internal enforcement rounds or major export order cycles.
Forward pricing to 2026 reflects a mix of raw material cost inflation, labor and energy cost pressure, and tightening global regulatory standards for API precursors. Anticipated consolidation among key producers in China and technological process upgrades to comply with stricter environmental controls may temporarily reduce available export volumes, lifting prices during transitional periods. Data input for forecasts aggregates actual traded transaction reports, primary supplier feedback, and spot market bidding outcomes, supplemented by import/export statistics from customs authorities and industry analyst assessments. Confidence in forecasts depends on regulatory continuity and absence of new major trade restrictions or supply chain shocks.
Operators have seen output throttled in regions subject to new air and water emission standards, especially in eastern China’s key fine chemical provinces. Several local plants underwent forced upgrades or temporary shutdowns, creating short supply intervals that rippled through the global supply chain. In the US and EU, increased enforcement of API precursor trace impurity reporting has prompted both internal and supplier-driven review of quality control and analytical validation protocols.
Stricter documentation requirements under new international guidelines (such as ICH Q3D and revised GMP audit trails) have changed the economics of supplying pharmaceutical-grade intermediates. Enhanced scrutiny of nitrosamine and genotoxic impurity risk in intermediates extends to both analytical batch releases and in-process controls. Supplier qualifications now depend not only on formal certification but also on demonstrated ability to adapt QA/QC systems to evolving audit criteria.
In response to market and regulatory challenges, production teams focus on multi-sourcing of critical inputs, rationalization of process bottlenecks to buffer output against line interruptions, and reinforcement of analytical release throughput. Batch consistency and expanded documentation trails, including chain-of-custody capture for all major grade lots, stand as dual priorities. Where compliance upgrades have introduced cost discontinuities, transparent communication with downstream partners and coordinated compliance upgrade schedules help reduce supply risk and maintain long-term buyer trust.
Clarithromycin intermediates belong mainly in the pharmaceutical sector, with primary use in macrolide antibiotic synthesis pipelines. Bulk pharmaceutical manufacturing, advanced intermediates processing, and contract manufacturing operations all rely on carefully defined grades tailored to downstream compound efficiency and impurity management.
Besides pharmaceutical actives, this chemistry may contribute to limited R&D programs in academic or veterinary medicine sectors, but the bulk of demand aligns to human-use regulated APIs.
| Industry Segment | Typical Grade | Control Focus |
|---|---|---|
| API Manufacturing (Regulated) | Pharma/USP/EP/JP compliant | Identity, purity, trace metal content, process impurities, residual solvents |
| Process Development | Intermediate/Process R&D grade | Impurity profile, scalability, reproducibility, analytical support |
| Veterinary/Non-GMP Bulk | Technical or industrial grade | Gross purity, functional performance, batch size flexibility |
For regulated API step production, impurity control dominates process validation and final lot release. Key parameters shift accordingly:
Each application field triggers a unique blend of analytical, documentation, and traceability requirements.
Determining whether the target process involves regulated API manufacture, bulk process development, or non-human veterinary context steers grade choices from the outset. Manufacturing aims for full alignment between supplied grade and the final registration or process requirement.
Projects bound by pharmacopeial standards (USP, EP, JP, ChP) demand grades produced under GMP or equivalent controls, with all quality documentation and audit support in place. Applications outside direct API supply may accept less stringent process-level controls, but clear definition is required at the specification stage.
Higher purity costs more, so technical-grade intermediates suffice for screening or non-medicinal pipelines. Purity demands grow with progression to human-use registration batches, where low-level organic impurity documentation and elemental impurity clearance become pivotal. Manufacturing works closely with quality to target the right impurity profile for each customer’s intended synthesis step.
Pilot, development, or kilo-lab projects may need flexibility in minimum order size and lot uniformity. Larger campaigns expect lot integration and stable supply. Budget planning considers both upfront analytical specification and the recurring costs of compliance testing, stability monitoring, and documentation support.
Final grade decisions often depend on in-lab validation. Manufacturing teams support sampling with chain-of-custody traceability and detailed Certificates of Analysis. Cross-lab verification ensures process compatibility, impurity clearance, and physical form suit intended use. Customer feedback on trial runs may drive adjustments to grade, specification, or manufacturing route.
Quality assurance extends from the earliest raw material selection through to the final intermediate released for shipment. Our production base operates under international standards that address both continuity of quality management and process traceability. Typical certifications for sites producing pharmaceutical intermediates include ISO 9001 for management systems. The focus in actual operation covers compliance with international guidelines such as cGMP principles where required by customer end-use, supported by regular third-party audits. Whether producing for regulated or non-regulated markets, documented traceability from raw input to released batch is integrated by our technical quality teams.
Clarithromycin Intermediate grades destined for use in regulated pharmaceutical supply chains demand greater depth of documentation and periodic re-validation of process controls. Product batches intended for regulated and high-specification markets are qualified through additional documentation, such as certificates of analysis (COA) that detail specific impurity profiles, and may be supported by process validation summaries when required. For non-pharma or technical-grade customers, batch-wise COA and basic technical data sheets provide necessary detail regarding chemical and physical characteristics as needed for each application.
We maintain a structured documentation and reporting protocol for each production lot. COA routinely includes assay, main impurity levels as per route-specific synthetic profile, moisture content, and appearance. MSDS/ SDS is supplied in region-appropriate formats. Upon request, complete dossiers on synthesis route selection, impurity management approach, and supporting analytical method validation are reviewed with key customers, particularly for those with downstream regulatory submission requirements. Site audits and inspection reports are available for qualified partners seeking full chain-of-custody transparency.
Capacity planning draws directly from actual production experience. We commission multipurpose reactors for each campaign and manage core intermediates with dedicated isolation and purification facilities. Historical supply performance demonstrates that, by maintaining a rolling buffer stock based on forecast and call-off agreements, downstream users can rely on on-time shipment for both standard and rush volumes. For project-based or emerging demand scenarios, flexible supply solutions are available—monthly, quarterly or as consignment plans reflecting specific customer procurement models.
For key Clarithromycin Intermediate grades, sustained production utilizes standardized process controls and monitored critical parameters at every major process step. IPCs (in-process controls) are mapped to ensure consistent output, and trend analysis flags deviation before it impacts the downstream batch. Our supply chain team interfaces with sourcing and regulatory groups to maintain up-to-date compliance on raw materials critical to synthesis. Lead times remain closely linked to prior batch cycle data and real-time procurement feedback from our partners.
Technical sample requests are handled as part of the project evaluation process. Upon formal inquiry, a technical sales manager or chemist reviews the intended downstream application, clarifies necessary specification ranges, and confirms required documentation. Shipping samples follows labelling and packaging per handling and transport best practices, always including a full analytical profile. Response times for sample provision reflect batch campaign scheduling and grade-specific material allocation.
Each customer project may require a distinct cooperation framework. We support supply through both fixed-term contracts and rolling purchase frameworks tied to project timelines or regulatory milestones. For customers engaged in scale-up or new product introductions, we provide phased deliveries, optioned shipment schedules, and integrated technical service—ensuring process changes or specification updates are reflected in upcoming batches. Responsive adjustments can be made to supply volumes and packaging modes according to real-time project feedback. From pilot trials through commercial volume, the production and business teams keep direct communication with technical and procurement counterparts to align production batch size, release schedules, and document packages with practical project needs.
Clarithromycin intermediates face strict scrutiny regarding impurity profiles and consistent yield. Most industrial R&D initiatives focus on refining process routes to minimize byproducts during glycosylation and N-demethylation steps. Attention is now directed at continuous-flow synthesis, offering benefits in consistency and cost management—subject to investment in equipment and real-time analytics. Where batch production still dominates, optimizing catalyst selection and raw material purity remains a central concern. Route selection often weighs solvent toxicity against environmental and operator safety, with R&D teams evaluating alternative green solvents, though technical substitution remains limited by solubility and reaction rate concerns.
Pharma-grade clarithromycin intermediate increasingly enters custom synthesis chains for next-generation macrolide analogs. Some users in regulated markets want intermediates with reduced residual solvent levels or specially controlled particle size. Emerging demand also comes from veterinary and specialty formulations, where impurity carryover can impact downstream bioactivity or formulation stability. Customization for these uses prompts manufacturers to tailor in-process controls, particularly in impurity removal and solid-state form management.
The main technical bottleneck involves purification from closely related impurities generated during fermentation and semi-synthetic steps. Reproducible crystallization is sensitive to minor batch-to-batch variations in upstream raw materials, leading to unpredictable filtration and drying characteristics. Some firms pursue membrane-based separations, but widespread adoption is hampered by fouling and scale-up risk. Process analytical technology (PAT) supports tighter control of critical parameters, allowing more precise endpoint detection and minimizing off-spec material. Sustained improvements in trace impurity identification via LC-MS and NMR drive more targeted process refinement, but regulatory and cost barriers slow commercial rollout of novel routes.
Global interest in macrolide antibiotics, driven by resistance trends and new indication studies, supports stable demand for clarithromycin intermediates. Growth rates in mature markets show gradual upticks linked to lifecycle management of branded products, while emerging regions follow a more project-driven, variable pattern. Evolution in regulatory requirements, especially in trace genotoxic impurity control, prompts many buyers to prefer direct-from-manufacturer procurement over third-party blending, as this enables tighter batch provenance and documentation. Price competition is likely to persist as efficiencies improve and new entrants adopt more automated or integrated production systems.
Ongoing transition toward continuous-flow and automated batch production brings efficiency and reproducibility benefits. Process intensification, especially in acid-mediated steps, relies on real-time process feedback to avoid side reaction buildup. Batch automation tools enable faster cycle times, but require robust raw material specification and pre-qualification of technical parameters. Discrete batch versus flow process selection remains grade- and volume-dependent; higher grades for regulated pharma markets require more detailed validation and process traceability. New solvent recovery and recycling systems enhance cost structure where permitted by product grade and regulatory needs.
Environmental drivers push process redesign to limit hazardous effluent, especially chlorinated and aromatic waste. Efforts to phase out solvents with high toxicity or persistence in the environment require close coordination with downstream users, as solubility and crystallization profile of the intermediate can shift substantially. Carbon footprint monitoring for intermediates is increasingly requested in supplier audits. Manufacturing adapts by optimizing energy use in filtration and drying, and by sourcing renewable feedstocks where technically feasible. Adopting green chemistry, though still technically constrained in some synthetic steps, often drives competitive advantage among multinational customers.
Direct technical support covers detailed process understanding, including impurity mapping, retesting protocols, and guidance on secondary manufacturing compatibility. Many industrial buyers seek root cause analysis for out-of-spec lots or formulation issues, which requires access to batch records, quality control (QC) data, and, when necessary, full impurity profiling using advanced instrumentation. Technical teams liaise with customer R&D and QC departments to adapt manufacturing specifications for special project needs, adjusting control points to match local regulatory or end-use requirements.
Manufacturing teams provide advice on formulation transfer, scale-up, and requalification of the intermediate in new settings. This includes guidance on particle size management, moisture sensitivity, and interaction with formulation excipients. Where the application is sensitive to solid-state form or requires extra control on trace metals and solvent residues, dedicated analytical support addresses questions of reproducibility and risk management. Application-specific support frequently involves site visits, sample tracking, and rapid feedback for process troubleshooting during initial use or validation batches.
Ongoing support covers complaint handling, technical investigations, and full lot traceability. Corrective action for deviation or complaint cases follows structured failure mode analysis, supported by documented QC and process data. Batch consistency management frameworks allow for transparent reporting to customers, including detailed deviation logs and, if necessary, suggested process adjustments downstream. For multi-year supply or high-grade contracts, support extends to regular technical exchange meetings and collaborative improvement projects for both cost and quality improvement. Release criteria always align with the customer-defined standard or, in the absence of such, the manufacturer’s internal release parameters established through validated process controls and historical performance data.
Specializing in the full-scale production of Clarithromycin intermediates, our plant supports leading pharmaceutical synthesis routes across major markets. Production lines adhere to industry-demanded throughput ratios, allowing us to consistently deliver high-purity intermediates in volumes required by both bulk active pharmaceutical ingredient (API) facilities and contract manufacturing partners. Each process sequence receives real-time analytical support, including in-process HPLC and final batch verification using validated reference standards.
Clarithromycin intermediates serve as essential starting points for manufacturing macrolide antibiotics. Our output enables direct integration with automated synthesis tracks, sterile compounding units, and continuous-flow reactors. Extensive feedback from downstream users in both generic and branded medicine manufacturing confirms robust yield efficiency and compatibility with high-throughput and custom API finishing stages. Large formulators across Asia, North America, and Western Europe routinely specify our intermediates to support commercial-scale antimicrobial lines, oral dosage projects, and injectable production branches.
Product consistency begins with feedstock selection under controlled vendor qualification, but the difference lies in our locked-down batch tracking and release system. Every stage of synthesis—starting from raw material intake to final intermediate packaging—receives validated analytical oversight. Standardized retention sampling, environmental monitoring in cleanrooms, and periodic third-party audits guarantee adherence to regulatory targets and client-defined specifications. Traceability plays an integral role; customers gain full reference to lot documentation and analytical certifications with each shipment.
Scaled output allows flexible handling of both multi-ton and smaller GMP-grade orders without bottleneck risks. We package Clarithromycin intermediates under nitrogen-purged conditions using multi-layer laminated containers to preserve chemical integrity regardless of travel distance or storage timelines. All supply units pass stability benchmarking for both temperature and humidity stress profiles. Our logistics team manages direct loading and secured shipment routes to ensure uninterrupted procurement and no double-handling transitions between the factory and the customer's site.
Our technical service team, composed of process development chemists and industrial pharmacists, responds directly to client queries on batch reactivity, solubility parameters, and integration into proprietary processes. Site visits accommodate process scale-up meetings, technology transfer consultations, and troubleshooting of plant-level application issues. Industrial buyers can expect full upstream and downstream support—ranging from analytical method guidance to regulatory documentation packages used for validation and compliance audits.
Manufacturers and commercial buyers benefit from partnership rooted in direct material control and transparent plant-to-client communication. By anchoring all specifications, QA protocols, and delivery schedules within our own operation, we eliminate risks linked to fragmented or brokered supply chains. Distributors gain reliability for diverse customer demands and reduced delays due to back-to-back manufacturer verification. Procurement teams secure predictable pricing frameworks, audit-ready traceability records, and early insight into production planning or capacity adjustments in response to dynamic market shifts.
As a direct manufacturer of clarithromycin intermediates, we closely monitor each batch throughout synthesis and quality control. Clarity and reliability in product specifications drive consistency in downstream processes. In this editorial, we address some key chemical properties and why tight purity specifications hold a central role in manufacturing clarithromycin intermediates used in pharmaceutical environments.
Clarithromycin intermediates are complex molecules, typically derived from macrolide structures. Many of these intermediates contain sensitive functional groups, especially lactone rings and deoxy sugar moieties. These can be prone to rearrangement, hydrolysis, or undesired side-product formation if not handled under strictly controlled conditions. Moisture can initiate hydrolysis, temperature fluctuations affect stability, and impure solvents may bring about cascading complications in yield and downstream conversion.
Our process chemistry emphasizes the importance of robust reaction controls. For example, maintaining narrow temperature ranges during alkylation or acylation ensures critical stereochemistry—most notably at the 6- and 9-positions of the macrolide ring. We invest in advanced analytical resources to ensure high-fidelity identification of such features in each manufactured batch. Structural integrity stays unchanged throughout all intermediates: from the initial crude synthesis through to the isolations preceding final clarithromycin coupling and purification.
In macrolide intermediates, even trace process impurities and residual solvents can endure through multiple synthetic steps, accumulating in the final product. Our facilities deploy high-performance liquid chromatography, mass spectrometry, and other analytical methods to confirm purity down to parts-per-million. Process controls target minimal residual organic solvents—each documented in line with major pharmacopeial requirements.
For each lot, assay values consistently exceed 99%. Total impurity levels remain well below established pharmaceutical thresholds. Besides related substances, we monitor water content using Karl Fischer titration, since excessive moisture compromises both storage stability and reactivity in the next step. Our standard protocol only releases intermediates that match both our own benchmarks and those demanded by downstream large-scale pharmaceutical synthesis.
As a manufacturer with years of experience in macrolide chemistry, we understand the risk of cross-contamination and false positives in impurity tests. We maintain segregated production lines for clarithromycin intermediates, strictly cleaning reactors and feed lines with validated cycles between campaigns. Our operators vigilantly record every transfer, every filtration, every drying run—no shortcuts.
Upon passing all tests, each batch is sealed under inert gas in export-standard containers. Labels reflect lot number, manufacturing date, net weight, and storage direction (usually cool and dry spaces, away from light). At the customer’s request, we support COA documentation, including full impurity profiles and heavy metal analysis, to facilitate qualification and regulatory submission on the customer’s end.
Our team actively collaborates with R&D divisions at leading pharma companies to support ongoing process optimization. As regulatory expectations evolve, we constantly review our analytical coverage and update testing methodologies. Any deviation detected at the analytical stage results in a comprehensive root cause analysis and corrective action before shipment.
We treat clarithromycin intermediates as more than commodities—their performance directly affects the efficacy, safety, and yield of the finished active pharmaceutical ingredient. Manufacturing is not just about producing molecules but about guaranteeing reliability and repeatability every single time. Our commitment rests on proven process controls, rigorous purity assurance, and consistent transparency with our production data. For technical specifications or custom requirements, our technical team supports direct discussion throughout the inquiry and order cycle.
Every customer asks about minimum order quantities and lead times for Clarithromycin Intermediate. Manufacturing this compound is a complex process. Raw materials undergo multiple synthesis steps, monitored at every stage by our in-house QC team. Maintaining this level of quality control puts a baseline on how little and how fast we can reliably ship.
For Clarithromycin Intermediate, our minimum order quantity typically starts at 25 kilograms. That aligns with our batch reactor volumes and the requirements for safe packaging and shipping. Producing less in one run does not lower per-unit costs, it actually increases waste and overhead. We have optimized our process over years to ensure that batching below this threshold does not compromise our controls or delay timelines for other pharmaceutical clients.
Some customers may need smaller samples for trial formulations or QC purposes. In these cases, we provide smaller quantities from retained samples of recent full-production batches, not off-specification or leftover material. This guarantees product consistency for analytical work or pilot runs. Our technical team also supports analytical data and documentation for these sample lots, so that R&D teams receive full traceability.
For a standard batch of Clarithromycin Intermediate, our production lead time typically falls between four and six weeks. This window covers raw material sourcing, multi-step synthesis, purification, and a full range of analytical testing before release. Quality checks include HPLC analysis, residual solvents, and microbiological testing according to current pharmacopoeia requirements. We only release and pack product that satisfies all these checkpoints. No shipment leaves our factory without documented confirmation of quality.
We keep core raw materials in stock to avoid long procurement delays. But global logistics and supply chain bottlenecks can shift timelines for specific precursors or solvents. When disruptions occur, we inform our customers immediately and propose feasible alternatives or adjusted schedules. On occasion, priority or repeat clients can leverage our reserve inventory for shorter lead times – this hinges on consecutive production runs and forecasting patterns.
Over the years, we have learned that transparent scheduling helps our clients keep their own production on track, whether for APIs or finished dosage forms. We provide regular updates during the synthesis, QA, and documentation stages, so customers can align their internal processes or regulatory filings. For larger campaigns, we work directly with procurement and planning teams to secure production slots and consistent delivery intervals.
Our production managers constantly review capacity planning, especially during high-demand periods or regulatory changes in the pharmaceutical sector. Scaling up batch size presents more than just technical hurdles: it requires real-time QC expansion, stability monitoring, and increased focus on waste management and environmental controls. We review each custom order for compliance risk and process bottlenecks before confirming the schedule.
Years of direct manufacturing experience in macrolide intermediates like Clarithromycin have shaped our systems. We do not overpromise, and our staff takes pride in real-world reliability, from weighing the first reactant to releasing the final certificate of analysis. Our clients count on us for products that arrive as specified, on schedule, and with clear supporting documentation.
Exporting Clarithromycin intermediates into global markets rarely follows a one-size-fits-all pattern. Each country brings its own detailed set of import and export regulations for chemicals involved in pharmaceutical manufacturing. As the producer, we have experienced, firsthand, how shifting policies can quickly impact the movement of our product and on-time delivery to our partners. Careless handling of certifications or incomplete documentation causes unnecessary shipment delays, sometimes even customs seizures. A hands-on approach to compliance saves resources for everyone in the value chain.
Clarithromycin intermediates are not simple chemicals—they are regulated as key materials in manufacturing macrolide antibiotics worldwide. On the export side, we maintain an export license that specifically allows us to ship the intermediate to permitted destinations. Our facility itself operates under a valid Drug Manufacturing License and follows Good Manufacturing Practices. We maintain batch records, traceability, and full documentation to comply with government and client audit requests.
On the import side, requirements often differ region by region. In the European Union, the shipment must clear REACH registration for chemicals and comply with the EU’s strict documentation expectations. Regulatory authorities may request data supporting quality, traceability, purity, and consistency. In the United States, shipment clearance often relies on Drug Master Files and certificates of analysis that validate each batch. Emerging markets have increased inspections and focus on imported intermediates after several high-profile contamination incidents in recent years. In our experience, most international customers ask for detailed technical dossiers, cGMP compliance statements, and supporting documentation like a Certificate of Origin. Without these, customs authorities in some countries deny entry, resulting in costly returns or destruction.
Our teams often coordinate directly with legal and logistic partners to stay ahead of evolving rules. For example, some destinations implement temporary import bans or require pre-shipment inspections after local drug safety incidents. We assign compliance managers who track regulatory changes in key destination markets. This keeps us ready to provide updated documentation, swiftly respond to new government decrees, and avoid shipment bottlenecks. In China, the Ministry of Commerce and Customs require specific HS codes for pharmaceutical intermediates; in India, all pharmaceutical imports need formal registration along with supporting technical documentation. An oversight as small as a missing signature or incomplete Certificate of Analysis can result in costly holdups. Experienced manufacturers know the value of proactive communication and detailed paperwork in every consignment. We do not ship overseas without confirming all destination regulations and trade restrictions upfront. Where import permits are mandatory, we coordinate directly with clients’ regulatory departments to file in advance.
Serious manufacturers understand the market’s expectation for verification beyond a simple regulatory checkbox. Beyond formal compliance, we invest in robust batch testing, traceability protocols, and frequent internal audits. A comprehensive compliance file—covering everything from HACCP plans to Material Safety Data Sheets—moves with every batch. These investments bolster customers’ confidence and equip regulatory authorities with what they expect during spot checks or port inspections. Our technical teams stand ready to assist with product data, COAs, packing lists, customs language, or supplementary details for destination authorities to review as needed.
Shipping a Clarithromycin intermediate across borders is a process shaped by continuous attention, extensive regulatory know-how, and a reputation for reliability. Those strengths allow us to keep strong partnerships alive—even as the international landscape evolves.
For product inquiries, sample requests, quotations or after-sales support, please feel free to contact me directly via sales3@ascent-chem.com, +8615365186327 or WhatsApp: +8615365186327
